Apogee Therapeutics (APGE) Accounts Payables (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Accounts Payables data on file, last reported at $1.2 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $1.2 million, down 49.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (down 49.41% YoY), and the FY2025 annual result was $1.2 million, up 14.01% from the prior year.
• Accounts Payables rose to $1.2 million in Q1 2026 per APGE's latest filing, from $1.2 million in the prior quarter.
• Over five years, Accounts Payables peaked at $11.1 million in Q2 2023 and troughed at $376000.0 in Q3 2025.
• A 5-year average of $3.0 million and a median of $2.1 million in 2023 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2023 and 2025: Accounts Payables soared 412.68% in 2023, then sank 83.03% in 2025.
• A 5-year view of Accounts Payables shows it stood at $418000.0 in 2022, then soared by 412.68% to $2.1 million in 2023, then plunged by 50.02% to $1.1 million in 2024, then grew by 14.01% to $1.2 million in 2025, then climbed by 1.31% to $1.2 million in 2026.
• Business Quant data shows APGE's Accounts Payables at $1.2 million in Q1 2026, $1.2 million in Q4 2025, and $376000.0 in Q3 2025.